Section 4.8: Clinical Pharmacology: Respiratory & Pulmonary Disorders

Clinical Pharmacology: Respiratory & Pulmonary Disorders

Respiratory and pulmonary disorders represent a significant portion of the Saudi Pharmacist Licensure Examination (SPLE) clinical sciences blueprint. Pharmacists must understand the pathophysiology, therapeutic guidelines, drug mechanisms of action, adverse effect profiles, and safety monitoring requirements for asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, and pulmonary arterial hypertension (PAH).

---

1. Asthma Management (GINA 2024 / Saudi Guidelines)

Asthma is a heterogeneous chronic inflammatory disease of the airways characterized by bronchial hyperresponsiveness and variable airflow obstruction. The Global Initiative for Asthma (GINA) guidelines specify two tracks for treatment, with Track 1 being the preferred approach for adult and adolescent patients.

GINA Tracks Overview

• Track 1 (Preferred): Uses low-dose inhaled corticosteroid (ICS) + formoterol as the reliever across all steps. This approach ensures that the patient receives anti-inflammatory therapy whenever reliever therapy is needed, mitigating the risk of severe exacerbations. SABA-only treatment is no longer recommended due to the risk of rebound hyperresponsiveness and increased mortality.
• Track 2 (Alternative): Uses a short-acting beta-2 agonist (SABA) as the reliever. This track requires strict adherence to daily maintenance ICS to prevent exacerbations. If a patient is poorly adherent to their maintenance inhaler, they are at high risk of severe asthma attacks.

Stepwise Management (Ages 12+)

Severe Asthma & Biologics

For patients on Step 5 therapy, phenotypic assessment guides the selection of monoclonal antibodies:

• Omalizumab: Anti-IgE recombinant antibody. Indicated for severe allergic asthma with elevated serum IgE levels.
• Mepolizumab & Benralizumab: Anti-interleukin-5 (IL-5) antibodies (Mepolizumab targets IL-5 ligand, Benralizumab targets IL-5 receptor alpha). Indicated for severe eosinophilic asthma.
• Dupilumab: Anti-IL-4 receptor alpha antibody (blocks IL-4 and IL-13 signaling). Indicated for severe eosinophilic asthma or patients dependent on oral corticosteroids.

---

2. COPD Management (GOLD 2024 / Saudi Guidelines)

Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent, progressive respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities (typically caused by tobacco smoke or biomass exposure). Unlike asthma, COPD is generally progressive and not fully reversible.

GOLD ABE Assessment Tool

COPD pharmacotherapy is guided by the patient's exacerbation history and symptom burden, measured by the modified Medical Research Council (mMRC) dyspnea scale or the COPD Assessment Test (CAT).

  Exacerbation History:
  >= 2 moderate exacerbations OR
  >= 1 leading to hospitalization   -----> Group E (LAMA + LABA; consider adding ICS if blood eosinophils >= 300 cells/mcL)
  
  0-1 moderate exacerbations (none leading to hospitalization):
  - mMRC 0-1, CAT < 10            -----> Group A (Single bronchodilator: LAMA or LABA)
  - mMRC >= 2, CAT >= 10          -----> Group B (LAMA + LABA)

Pharmacotherapy Classes and Roles

• Long-Acting Muscarinic Antagonists (LAMA): e.g., Tiotropium, Umeclidinium, Glycopyrrolate. Block M3 receptors on airway smooth muscle, causing bronchodilation. They are highly effective at reducing exacerbation frequency.
• Long-Acting Beta-2 Agonists (LABA): e.g., Salmeterol, Formoterol, Vilanterol. Stimulate beta-2 adrenergic receptors, leading to bronchodilation.
• Inhaled Corticosteroids (ICS): e.g., Fluticasone, Budesonide. Never used as monotherapy in COPD due to lack of efficacy and an increased risk of pneumonia. ICS should be added to LAMA+LABA dual therapy (triple therapy) only if the patient has a history of frequent exacerbations and a blood eosinophil count of >= 300 cells/mcL (or >= 100 cells/mcL with >= 2 moderate exacerbations or 1 hospitalization).

---

3. Allergic Rhinitis

Allergic rhinitis is an immunoglobulin E (IgE)-mediated inflammatory response of the nasal mucosa to airborne allergens. Pharmacists must distinguish between the efficacy and safety profiles of available treatments:

• Intranasal Corticosteroids (e.g., Fluticasone, Mometasone): The most effective treatment class for moderate-to-severe symptoms. They downregulate local inflammatory cytokines. Side effects include nasal dryness, burning, and epistaxis.
• Antihistamines (H1-receptor antagonists):
  • First-Generation (e.g., Diphenhydramine, Chlorpheniramine, Hydroxyzine): Highly lipophilic and cross the blood-brain barrier. They cause marked sedation, cognitive impairment, and anticholinergic effects (dry mouth, urinary retention, blurred vision). They are avoided in elderly patients.
  • Second-Generation (e.g., Loratadine, Cetirizine, Fexofenadine): Highly hydrophilic and do not readily cross the blood-brain barrier. Fexofenadine and Loratadine are non-sedating, while Cetirizine can cause mild sedation in sensitive individuals.
  • Intranasal (e.g., Azelastine, Olopatadine): Provide rapid symptom relief with a bitter taste as a common side effect.
• Leukotriene Receptor Antagonists (e.g., Montelukast): Indicated for patients with concomitant asthma. However, pharmacists must counsel on the FDA Black Box Warning for serious neuropsychiatric events, including agitation, depression, and suicidal ideation.

---

4. Pulmonary Arterial Hypertension (PAH)

PAH (WHO Group 1) is a rare, progressive disease characterized by elevated pulmonary vascular resistance leading to right ventricular failure. It is diagnosed by right heart catheterization showing a mean pulmonary artery pressure (mPAP) > 20 mmHg with normal pulmonary capillary wedge pressure (PCWP <= 15 mmHg).

Vasoreactivity Testing & Treatment Algorithm

All patients must undergo acute vasoreactivity testing during right heart catheterization, usually using inhaled nitric oxide:

• Responders (Positive Response): Defined as a decrease in mPAP by >= 10 mmHg to an absolute value <= 40 mmHg with a stable or increased cardiac output. These patients are treated with high-dose oral Calcium Channel Blockers (CCBs): Amlodipine, Nifedipine ER, or Diltiazem. Verapamil is avoided due to negative inotropic effects.
• Non-responders (Negative Response): Require specialized PAH-targeted drug classes: